Retirement stocks are something every investor needs to look into, and when deciding on which retirement stocks to buy, you can never go wrong with Dividend Kings, S&P 500 index constituents that have raised their dividends every one of the previous 25 straight years.Dividend growers had 11.7% compound annual returns from 1986 to 2016, while dividend payers had 9.9%. Dividend stocks are more resilient, so this outperformance is even greater during market volatility. This is great, since the markets are stil ...

These reliable dividend payers are no-brainer buys right now.It's been a big year for most stocks, with the S&P 500 index up about 24% over the past 12 months. A rising market is wonderful for the stocks already in your portfolio, but finding new investment opportunities is a lot more challenging than it was a year ago.A buoyant stock market makes it harder to find compelling investment opportunities, but not if you know where to look. With artificial intelligence-related businesses absorbing most investors ...

AbbVie (ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending granting conditional marketing authorization for the expanded use of its drug Tepkinly (epcoritamab) for treating relapsed/refractory follicular lymphoma (R/R FL).AbbVie is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with R/R FL after two or more prior therapies. The European Commission’s decis ...

Core Points - AbbVie has announced the appointment of Robert A. Michael as the new CEO, succeeding Richard A. Gonzalez, who will now serve as executive chairman [1][2] - Robert A. Michael has extensive experience in various leadership roles within AbbVie, including president and chief operating officer, and has been part of the Executive Leadership Team for many years [2][3] - The transition in leadership is aimed at continuing AbbVie's mission to deliver innovative medicines and to drive the next phase of growth for the company [3][4] Company Overview - AbbVie's mission focuses on discovering and delivering innovative medicines that address serious health issues and future medical challenges across key therapeutic areas such as immunology, oncology, neuroscience, and eye care [4]

These stocks could be ideal for investors in their golden years.Most retirees prefer low turnover in their investment portfolios. The less drama, the better. That way, they can focus on doing what they enjoy instead of worrying about their investments.Three Motley Fool contributors think they've found magnificent stocks retirees can buy and hold forever. Here's why they picked AbbVie (ABBV 1.50%), Gilead Sciences (GILD -0.32%), and Johnson & Johnson (JNJ 0.25%).A Dividend King poised for growthKeith Speight ...

AbbVie (ABBV) announced that it has acquired Celsius Therapeutics, a private biotech making novel therapies for treating inflammatory bowel diseases (“IBD”).The acquisition will add Celsius Therapeutics’ lead pipeline candidate, CEL383, to AbbVie’s pipeline. CEL383 is a potential first-in-class TREM1 inhibitor, which has completed phase I study in IBD conditions. AbbVie will pursue further development of CEL383.TREM1 has been identified as a key gene involved in inflammation pathways associated with IBD. In ...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyPositive CHMP opinion based on results from the Phase 1/2 EPCORE® NHL-1 studyNORTH CHICAGO, Ill., June 28, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's (EMA) ...

AbbVie (ABBV) announced that the FDA approved its lymphoma drug Epkinly (epcoritamab) for a second indication — follicular lymphoma (FL). The drug has been developed in partnership with Genmab (GMAB) .The FDA approved Epkinlyunder the accelerated pathway to treat adults with relapsed or refractory (R/R) FL after two or more lines of therapies. The agency initially granted accelerated approval to the drug last year to treat patients with R/R diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphom ...

AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this drugmaker have returned +10.6% over the past month versus the Zacks S&P 500 composite's +3.4% change. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has gained 5.2% over this period. Now the key question is: Where could the stock be headed in the near term?Although ...

Celsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibod ...